Novel analogues of the anti-HIV-1 lead compound [1-[2‘,5’-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]thymine]-3‘-spiro-5’-(4“-amino-1”,2“-oxathiole-2‘,2’-dioxide) (TSAO-T) bearing different amino acids at position N-3 of thymine were prepared and evaluated as inhibitors of HIV replication. The synthesis of the target compounds was accomplished by coupling of the appropriate TSAO intermediate with a conveniently protected (L) amino acid in the presence of BOP and triethylamine, followed by depro-tection of the amino acid moiety. Several TSAO derivatives, bearing at N-3 position of the thymine base an L-amino acid retaining the free carboxylic acid, acquired activity against HIV-2, in addition to their inhibitory effect on HIV-1.
AlvarezRVelázquezSSan-FélixAAquaroSDe ClercqEPernoCFKarlssonABalzariniJ & CamarasaMJ (1994) 1,2,3-Triazole-[2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3′-spiro-5“-(4”-amino-1“,2”-oxathiole-2“,2”-dioxide) (TSAO) analogues: Synthesis and anti-HIV-1 activity. Journal of Medicinal Chemistry37: 4185–4194.
2.
BalzariniJPérez-PérezMJSan-FélixAScholsDPernoCFVandammeAMCamarasaMJ & De ClercqE (1992a) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5“-(4”-amino-1“,2”-oxathiole-2“,2”-dioxide) pyrimidine (TSAO) nucleoside analogues: Highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA89: 4392–4396.
3.
BalzariniJPérez-PérezMJSan-FélixAVelázquezSCamarasaMJ & De ClercqE (1992b) [2′,5′-Bis-O-(tert-butyldimethylsilyl)]-3′-spiro-5“-(4”-amino-1“,2”-oxathiole-2“,2”-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy36: 1073–1080.
4.
BalzariniJPérez-PérezMJSan-FélixACamarasaMJBathurstICBarrPJ & De ClercqE. (1992c) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3′-spiro-5“-(4”-amin o-1“,2”-oxathiole-2“,2”-dioxide) thymine (TSAO-T). Journal of Biological Chemistry267: 11831–11838.
5.
BalzariniJCamarasaMJ & KarlssonA (1993) TSAO derivatives: Highly specific human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors. Drugs of the Future18: 1043–1055.
6.
BalzariniJKleimJPRiessGCamarasaMJDe ClercqE & KarlssonA (1994) Sensitivity of (138 GLU→LYS) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochemical and Biophysical Research Communications201: 1305–1312.
7.
BoyerPLDingJArnoldE & HughesSH (1994) Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy38: 1909–1914.
8.
CamarasaMJPérez-PérezMJSan-FélixABalzariniJ & De ClercqE (1992) 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: Synthesis and antiviral activity of [2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-xylo and -ribofuranose]-3′-spiro-5“-[4”-amino-1“,2”-oxathiole-2“,2”-dioxide] (TSAO) pyrimidine nucleosides. Journal of Medicinal Chemistry35: 2721–2727.
9.
CamarasaMJPérez-PérezMJVelázquezSSan-FélixAAlvarezRIngateSJimenoMLKarlssonADe ClercqE & BalzariniJ (1995) TSAO derivatives: Highly specific inhibitors of human immunodeficiency virus type-1 (HIV-1) replication. Nucleosides and Nucleotides14: 585–594.
10.
CastroBDormoyJREvinG & SelveC (1975) Reactifs de couplage peptidique IV (1)-L'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (B.O.P.), Tetrahedron Letters14: 1219–1222.
11.
GreensteinJP & WinitzM (Editors) (1961) Chemistry of Amino Acids, pp 569. New York and London: J Wiley & Sons.
12.
HarrisDLeeRMisraHSPandeyPK & PandeyVN (1998) The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry37: 5903–5908.
13.
JonckheereHTaymansJMBalzariniJVelázquezSCamarasaMJDesmyterJDe ClercqE & AnnéJ (1994) Resistance of HIV-1 reverse transcriptase against [2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5“-(4”-amino-1“,2”-oxathiole-2“,2”-dioxide)] (TSAO) derivatives is determined by the mutation Glu138→Lys on the p51 subunit. Journal of Biological Chemistry269: 25255–25258.
14.
KimMH & PatelDV (1994) “BOP” as a reagent for mild and efficient preparation of esters. Tetrahedron Letters35: 5603–5606.
15.
Pérez-PérezMJSan-FélixABalzariniJDe ClercqE & CamarasaMJ (1992) TSAO-analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3′-spiro-5“-(4”-amino-1“,2”-oxathiole-2“,2”-dioxi de)pyrimidine and pyrimidine-modified nucleosides. Journal of Medicinal Chemistry35: 2988–2995.
16.
San-FélixAVelázquezSPérez-PérezMJBalzariniJDe ClercqE & CamarasaMJ (1994) Novel Series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-,5-, and 6-substituted pyrimidine analogues. Journal of Medicinal Chemistry37: 453–460.
17.
VelázquezSSan-FélixAPérez-PérezMJBalzariniJDe ClercqE & CamarasaMJ (1993) TSAO-analogues 3. Synthesis and anti-HIV-1 activity of 2′,5′-Bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl-3′-spiro-5“-(4”-amino-1“, 2”-oxathiole-2“, 2”-dioxide) purine and purine-modified nucleosides. Journal of Medicinal Chemistry36: 3230–3239.
18.
VelázquezSAlvarezRPérezCGagoFDe ClercqEBalzariniJ & CamarasaMJ (1998a) Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcar-bamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues. Antiviral Chemistry and Chemotherapy9: 481–489.
19.
VelázquezSChamorroCPérez-PérezMJAlvarezRJimenoMLMartín-DomenechAPérezCGagoFDe ClercqEBalzariniJSan-FélixA, & CamarasaMJ (1998b) Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase. Journal of Medicinal Chemistry41: 4636–4647.
